Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,788.80
(
0.70%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.96
(
0.74%
)
Bitcoin
80,576.01
(
-0.59%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 115713

Wednesday, 05/11/2011 1:12:02 AM

Wednesday, May 11, 2011 1:12:02 AM

Post# of 257566
Roche submits PLX4032 NDA/MAA for BRAF-V600+ melanoma:

http://finance.yahoo.com/news/New-Drug-Applications-bw-1675487810.html?x=0&.v=1

PLX4032 (a/k/a vemurafenib) is the drug Roche licensed from Plexxikon that was the subject of a recent series in the NY Times (#msg-46899517, #msg-54567652). The phase-3 data (#msg-58950046) were sufficiently compelling that Daiichi Sanko bought Plexxikon for almost $1B two months ago (#msg-60475592).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today